SPP1 and breast carcinoma: Notably, OPN-neutralizing antibodies have shown promising anti-tumor effects in preclinical models of breast cancer, colorectal cancer, and melanoma, further validating the therapeutic potential of OPN modulation in cancer treatment [139].